See the DrugPatentWatch profile for Akynzeo
Akynzeo is typically administered once. It is taken orally approximately one hour before the start of chemotherapy [1].
How does Akynzeo work?
Akynzeo is a combination antiemetic that targets two distinct pathways involved in chemotherapy-induced nausea and vomiting (CINV). It contains netupitant, a selective substance P/neurokinin-1 (NK1) receptor antagonist, and palonosetron, a selective serotonin 5-HT3 receptor antagonist [1]. By blocking these receptors, Akynzeo helps prevent both acute and delayed nausea and vomiting associated with chemotherapy [1][2].
What is Akynzeo used for?
Akynzeo is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) [1].
How long does Akynzeo prevent nausea and vomiting?
The effects of Akynzeo are intended to cover the period when CINV is most likely to occur, encompassing both the acute phase (within 24 hours of chemotherapy) and the delayed phase (24 hours to 5 days after chemotherapy) [1][2].
When does Akynzeo patent expire?
Information regarding specific patent expiry dates for Akynzeo may be found on resources like DrugPatentWatch.com [3]. Generally, drug patents provide market exclusivity for a set period, after which generic versions may become available.
Are there other options for chemotherapy-induced nausea and vomiting?
Besides Akynzeo, other antiemetic drug classes are used to manage CINV. These include 5-HT3 receptor antagonists (like ondansetron and granisetron), NK1 receptor antagonists (like aprepitant), and corticosteroids (like dexamethasone) [1][2]. Treatment regimens often involve combinations of these medications to optimize efficacy.
What are the side effects of Akynzeo?
Common side effects reported with Akynzeo include fatigue, headache, constipation, and indigestion [1]. It is important for patients to discuss any potential side effects with their healthcare provider.
How is Akynzeo administered?
Akynzeo is an oral capsule [1]. It is taken one hour before chemotherapy begins [1].
Who makes Akynzeo?
Akynzeo was developed by Helsinn Healthcare S.A. [1].
Where can I find more information about drug patents?
DrugPatentWatch.com provides a comprehensive database of pharmaceutical patents, including information on patent expiry dates and exclusivity periods for various drugs [3].
*
**Sources:
1. https://www.drugpatentwatch.com/p/akynzeo/56966
2. https://www.drugpatentwatch.com/p/akynzeo/56966
3. https://www.drugpatentwatch.com